Axonis Therapeutics October 2024 Series A Funding Round

Axonis Therapeutics recently completed a $115 million Series A funding round, led by Cormorant Asset Management and venBio Partners. The funding will support clinical development of AXN-027, an innovative KCC2-targeting therapy for neurological disorders, particularly epilepsy and pain. Other major investors include Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and Lumira Ventures. Axonis CEO Joanna Stanicka highlighted the milestone's importance as they advance their research into patient treatments. The funding also allows Axonis to develop additional KCC2-focused compounds for various neurological conditions.